|
|||
DRUGS & SUPPLEMENTS
|
How often in a day do you take medicine? How many times? |
Diazepam:
Dericip Plus is a benzodiazepine derivative tranquilizer. It provides anxiolytic, sedative, anticonvulsant, central muscle relaxant effect. The mechanism of action is associated with increased inhibitory effect of GABA in the CNS. Muscle relaxant effect is also due to the inhibition of spinal reflexes. This medication may cause anticholinergic effects.
Dericip Plus (Diazepam) has rapid absorption. Cmax in plasma observed after 90 min. Plasma protein binding is 98%. Dericip Plus (Diazepam) crosses the placental barrier into the cerebrospinal fluid; excreted in breast milk; metabolized in the liver; excreted by the kidneys - 70%.
Dericip Plus prescribed for oral, IV, IM, rectal use. The daily dose of Dericip Plus (Diazepam) ranges from 0.5 mg to 60 mg. Single dose, frequency and duration of use are set individually.
CNS: drowsiness, dizziness, muscle weakness; rare - confusion, depression, blurred vision, diplopia, dysarthria, headache, tremor, ataxia; in single cases - a paradoxical response: excitement, anxiety, sleep disturbances, hallucinations. After IV injection is sometimes seen a hiccup. With prolonged use may develop drug dependence, memory impairment.
Digestive system: rarely - constipation, nausea, dry mouth, excessive salivation; in single cases - raising the level of transaminases and alkaline phosphatase in blood plasma, jaundice.
Endocrine system: rarely - increased or decreased libido.
Urinary system: rare - incontinence.
Cardiovascular system: when administered parenteral may be some fall in blood pressure.
Respiratory system: when administered parenteral in single cases - respiratory disorders.
Allergic reactions: rarely - a skin rash.
Myasthenia gravis, severe chronic hypercapnia. Specifying a history of alcohol or drug dependence. Hypersensitivity to Dericip Plus (Diazepam) and other benzodiazepines.
Dericip Plus (Diazepam) should not be used in the I trimester of pregnancy, except in cases of extreme necessity. Dericip Plus (Diazepam) taking during pregnancy may significantly change fetal heart rate.
When used in obstetrics doses recommended to facilitate childbirth, newborns (most preterm) it is possible temporary muscular hypotonia, hypothermia, respiratory failure.
When taken regularly during lactation breastfeeding should be discontinued.
Should avoid the use of Dericip Plus (Diazepam) in newborn infants, since they have not yet fully formed enzyme system involved in the metabolism of Dericip Plus (Diazepam).
Dericip Plus with caution used in patients with cardiac and respiratory failure, organic changes in the brain (in such cases are advised to avoid parenteral administration of Dericip Plus (Diazepam)), with angle-closure glaucoma and predisposition to it, in myasthenia.
There are needed special care when using Dericip Plus (Diazepam) (especially at the beginning of treatment) for patients receiving long-term antihypertensive medications of central action, beta-blockers, anticoagulants, cardiac glycosides.
If you cancel the therapy dose should be reduced gradually. With the sudden cancellation of Dericip Plus (Diazepam) after prolonged use may concern, excitement, tremors, convulsions. This medicine should be abolished in the development of paradoxical reactions (acute agitation, anxiety, sleep disturbances and hallucinations).
After I.M. injection of Dericip Plus (Diazepam) may increase the activity of CK in the blood plasma (which should be considered in the differential diagnosis of myocardial infarction).
Avoid IA injection.
Avoid alcohol during the period of treatment.
Dericip Plus (Diazepam) can cause slowing of psychomotor responses that should be considered for patients involved in potentially danger activities.
When used Dericip Plus (Diazepam) with drugs providing a depressing effect on the CNS (including with antipsychotics, sedatives, hypnotics, opioid analgesics, drugs for anesthesia), enhanced inhibitory effect on the central nervous system, the respiratory center, pronounced arterial hypotension.
When used Dericip Plus (Diazepam) with the tricyclic antidepressants (including amitriptyline) may be increasing of the CNS depressant effect, increasing concentrations of antidepressants and increased cholinergic action.
Patients receiving long-term antihypertensive medications central action, beta-blockers, anticoagulants, cardiac glycosides, the extent and mechanisms of drug interactions are unpredictable.
Simultaneous administration with muscle relaxants the action of muscle relaxants increases, also increases the risk of apnea.
Co-administration with oral contraceptives may increase the effects of Dericip Plus (Diazepam). The risk of breakthrough bleeding increases.
Simultaneous administration with bupivacaine may increase the concentration of bupivacaine in blood plasma; with diclofenac - may increase dizziness; with isoniazid - a decrease of Dericip Plus (Diazepam) elimination from the body.
Drugs that cause induction of liver enzymes, including antiepileptic drugs (carbamazepine, phenytoin) may accelerate the elimination of Dericip Plus (Diazepam).
When this medicine used with caffeine decreases sedative and possibly anxiolytic action of Dericip Plus (Diazepam).
Simultaneous administration with with clozapine may be expressed as hypotension, respiratory depression, loss of consciousness; with levodopa - may suppress antiparkinsonian action; with lithium carbonate - described a case of coma, with metoprolol - possible decreased visual acuity, impairment of psychomotor reactions.
Simultaneous administration with paracetamol may decrease excretion of Dericip Plus (Diazepam) and its metabolite desmethyldiazepam; with risperidone - described the cases of NMS.
Co-administration with rifampicin increased excretion of Dericip Plus (Diazepam) is due to a significant increase in its metabolism under the influence of rifampicin.
Theophylline at low doses changes a sedative effect of Dericip Plus (Diazepam).
In rare cases Dericip Plus (Diazepam) inhibits the metabolism and increases the effect of phenytoin. Phenobarbital and phenytoin may accelerate the metabolism of Dericip Plus (Diazepam).
Fluvoxamine increases plasma concentrations and side effects of Dericip Plus (Diazepam).
Cimetidine, omeprazole, disulfiram may increase the intensity and duration of action of Dericip Plus (Diazepam).
Alcohol and alcohol containing drugs enhanced inhibitory effect on the central nervous system (mainly on the respiratory center) but can also occur syndrome of pathological intoxication.
Symptoms: CNS depression of varying severity (from lethargy to coma): severe drowsiness, lethargy, weakness, decreased muscle tone, ataxia, prolonged confusion, depression of reflexes, coma; perhaps hypotension, respiratory depression.
Treatment: induction of vomiting and the appointment of activated charcoal (if the patient is conscious), gastric lavage through a tube (if patient is unconscious), symptomatic therapy, monitor vital functions, liquids' intravenous injection (to increase urine output), if necessary - artificial ventilation. With the development of excitation barbiturates should not be used. In hospital conditions used a benzodiazepine receptor antagonist flumazenil as specific antidote. Hemodialysis is ineffective.
Ephedrine:
FOR YOUR PROTECTION, DO NOT USE IF SEAL OVER MOUTH OF BOTTLE IS BROKEN OR MISSING. CAPUSLES ARE SEALED WITH A RED GELATIN BAND
(in each capsule)
Dericip Plus (Ephedrine) Sulfate USP, 25 mg
Bronchodilator
For temporary relief of shortness of breath, tightness of chest, and wheezing due to bronchial asthma. For the temporary relief of bronchial asthma. Eases breathing for asthma patients by reducing spasms of bronchial muscles.
Do not use this product unless a diagnosis of asthma has been made by a doctor. Do not use this product if you have heart disease, high blood pressure, thyroid disease, diabetes, or difficulty in urination due to enlargement of the prostate gland unless directed by a doctor. Do not use this product if you have ever been hospitalized for asthma or if you are taking and prescription drug for asthma or if you are taking and prescription drug for asthma unless directed by a doctor.
Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor of pharmacist before taking this product.
heart disease
high blood pressure
thyroid disease
diabetes
trouble urinating due to an enlarged prostate gland
Do not use more than directed. Nervousness, tremor, sleeplessness, nausea or loss of appetite may occur. Do not continue to use this product, but seek medical assistance immediately if symptoms are not relieved within 1 hour or become worse, consult your doctor.
Symptoms are not relieved within 1 hour or become worse. Nervousness, tremor or sleeplessness become worse. Some users of this product may experience nervousness, tremor, sleeplessness, nausea, and loss of appetite. If these symptoms persist or become worse, consult your doctor.
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away.
Adults and children 12 years of age and over: | Oral dosage is 12.5 to 25 milligrams every 4 hours, not to exceed 150 milligrams in 24 hours, or as directed by a doctor. Do not exceed recommended dose unless directed by a doctor. | |||
Children under 12 years of age: | Consult a doctor. |
Store at 20-25°C (68-77°F). Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. You may report side effects to FDA at 1-800-FDA-1088.
Colloidal Silicon Dioxide, Corn Starch, Magnesium Stearate. Capsule shell contains: FD&C Red #3 and Gelatin.
West-ward Pharmaceutical Corp.
Eatontown, N.J. 07724
Front
Back
Theophylline:
Dericip Plus (Theophylline)® (theophylline, anhydrous) Tablets in a controlled-release system allows a 24-hour dosing interval for appropriate patients.
Dericip Plus (Theophylline) is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous Dericip Plus (Theophylline) has the chemical name 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, and is represented by the following structural formula:
The molecular formula of anhydrous Dericip Plus (Theophylline) is C7H8N4O2 with a molecular weight of 180.17.
Each controlled-release tablet for oral administration, contains 400 or 600 mg of anhydrous Dericip Plus (Theophylline).
Inactive Ingredients: cetostearyl alcohol, hydroxyethyl cellulose, magnesium stearate, povidone and talc.
Dericip Plus (Theophylline) 400 mg
Dericip Plus has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While the mechanisms of action of Dericip Plus (Theophylline) are not known with certainty, studies in animals suggest that bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with Dericip Plus (Theophylline) appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).
Dericip Plus (Theophylline) increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.
Bronchodilation occurs over the serum Dericip Plus (Theophylline) concentration range of 5-20 mcg/mL. Clinically important improvement in symptom control has been found in most studies to require peak serum Dericip Plus (Theophylline) concentrations >10 mcg/mL, but patients with mild disease may benefit from lower concentrations. At serum Dericip Plus (Theophylline) concentrations >20 mcg/mL, both the frequency and severity of adverse reactions increase. In general, maintaining peak serum Dericip Plus (Theophylline) concentrations between 10 and 15 mcg/mL will achieve most of the drug’s potential therapeutic benefit while minimizing the risk of serious adverse events.
Overview: Dericip Plus is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form. Dericip Plus (Theophylline) does not undergo any appreciable pre-systemic elimination, distributes freely into fat-free tissues and is extensively metabolized in the liver.
The pharmacokinetics of Dericip Plus (Theophylline) vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology (see Table I ) and co-administration of other drugs (see Table II ) can significantly alter the pharmacokinetic characteristics of Dericip Plus (Theophylline). Within-subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum Dericip Plus (Theophylline) concentrations be measured frequently in acutely ill patients (e.g., at 24-hr intervals) and periodically in patients receiving long-term therapy, e.g., at 6-12 month intervals. More frequent measurements should be made in the presence of any condition that may significantly alter Dericip Plus (Theophylline) clearance (see PRECAUTIONS, Laboratory Tests ).
Population Characteristics | Total body clearance* mean (range)†† (mL/kg/min) | Half-life mean (range)†† (hr) | |
---|---|---|---|
¶For various North American patient populations from literature reports. Different rates of elimination and consequent dosage requirements have been observed among other peoples. | |||
*Clearance represents the volume of blood completely cleared of Dericip Plus (Theophylline) by the liver in one minute. Values listed were generally determined at serum Dericip Plus (Theophylline) concentrations <20 mcg/mL; clearance may decrease and half-life may increase at higher serum concentrations due to non-linear pharmacokinetics. | |||
††Reported range or estimated range (mean ±2 SD) where actual range not reported. | |||
†NR=not reported or not reported in a comparable format. | |||
**Median | |||
Age | |||
Premature neonates | |||
postnatal age 3-15 days | 0.29 (0.09-0.49) | 30 (17-43) | |
postnatal age 25-57 days | 0.64 (0.04-1.2) | 20 (9.4-30.6) | |
Term infants | |||
postnatal age 1-2 days | NR† | 25.7 (25-26.5) | |
postnatal age 3-30 weeks | NR† | 11 (6-29) | |
Children | |||
1-4 years | 1.7 (0.5-2.9) | 3.4 (1.2-5.6) | |
4-12 years | 1.6 (0.8-2.4) | NR† | |
13-15 years | 0.9 (0.48-1.3) | NR† | |
6-17 years | 1.4 (0.2-2.6) | 3.7 (1.5-5.9) | |
Adults (16-60 years) | |||
otherwise healthy | |||
non-smoking asthmatics | 0.65 (0.27-1.03) | 8.7 (6.1-12.8) | |
Elderly (>60 years) | |||
non-smokers with normal cardiac, liver, and renal function | 0.41 (0.21-0.61) | 9.8 (1.6-18) | |
Concurrent illness or altered physiological state | |||
Acute pulmonary edema | 0.33** (0.07-2.45) | 19** (3.1-82) | |
COPD->60 years, stable | |||
non-smoker >1 year | 0.54 (0.44-0.64) | 11 (9.4-12.6) | |
COPD with cor pulmonale | 0.48 (0.08-0.88) | NR† | |
Cystic fibrosis (14-28 years) | 1.25 (0.31-2.2) | 6.0 (1.8-10.2) | |
Fever associated with | |||
acute viral respiratory illness | |||
(children 9-15 years) | NR† | 7.0 (1.0-13) | |
Liver disease | |||
cirrhosis | 0.31** (0.1-0.7) | 32** (10-56) | |
acute hepatitis | 0.35 (0.25-0.45) | 19.2 (16.6-21.8) | |
cholestasis | 0.65 (0.25-1.45) | 14.4 (5.7-31.8) | |
Pregnancy | |||
1st trimester | NR† | 8.5 (3.1-13.9) | |
2nd trimester | NR† | 8.8 (3.8-13.8) | |
3rd trimester | NR† | 13.0 (8.4-17.6) | |
Sepsis with multi-organ failure | 0.47 (0.19-1.9) | 18.8 (6.3-24.1) | |
Thyroid disease | |||
hypothyroid | 0.38 (0.13-0.57) | 11.6 (8.2-25) | |
hyperthyroid | 0.8 (0.68-0.97) | 4.5 (3.7-5.6) |
Note: In addition to the factors listed above, Dericip Plus (Theophylline) clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of Dericip Plus (Theophylline).
Dericip Plus (Theophylline)® administered in the fed state is completely absorbed after oral administration.
In a single-dose crossover study, two 400 mg Dericip Plus (Theophylline) Tablets were administered to 19 normal volunteers in the morning or evening immediately following the same standardized meal (769 calories consisting of 97 grams carbohydrates, 33 grams protein and 27 grams fat). There was no evidence of dose dumping nor were there any significant differences in pharmacokinetic parameters attributable to time of drug administration. On the morning arm, the pharmacokinetic parameters were AUC=241.9±83.0 mcg hr/mL, Cmax=9.3±2.0 mcg/mL, Tmax=12.8±4.2 hours. On the evening arm, the pharmacokinetic parameters were AUC=219.7±83.0 mcg hr/mL, Cmax=9.2±2.0 mcg/mL, Tmax=12.5±4.2 hours.
A study in which Dericip Plus (Theophylline) 400 mg Tablets were administered to 17 fed adult asthmatics produced similar Dericip Plus (Theophylline) level-time curves when administered in the morning or evening. Serum levels were generally higher in the evening regimen but there were no statistically significant differences between the two regimens.
MORNING | EVENING | |
---|---|---|
AUC (0-24 hrs) (mcg hr/mL) | 236.0±76.7 | 256.0±80.4 |
Cmax (mcg/mL) | 14.5±4.1 | 16.3±4.5 |
Cmin (mcg/mL) | 5.5±2.9 | 5.0±2.5 |
Tmax (hours) | 8.1±3.7 | 10.1±4.1 |
A single-dose study in 15 normal fasting male volunteers whose Dericip Plus (Theophylline) inherent mean elimination half-life was verified by a liquid Dericip Plus (Theophylline) product to be 6.9±2.5 (SD) hours were administered two or three 400 mg Dericip Plus (Theophylline)® Tablets. The relative bioavailability of Dericip Plus (Theophylline) given in the fasting state in comparison to an immediate-release product was 59%. Peak serum Dericip Plus (Theophylline) levels occurred at 6.9±5.2 (SD) hours, with a normalized (to 800 mg) peak level being 6.2±2.1 (SD). The apparent elimination half-life for the 400 mg Dericip Plus (Theophylline) Tablets was 17.2±5.8 (SD) hours.
Steady-state pharmacokinetics were determined in a study in 12 fasted patients with chronic reversible obstructive pulmonary disease. All were dosed with two 400 mg Dericip Plus (Theophylline) Tablets given once daily in the morning and a reference controlled-release BID product administered as two 200 mg tablets given 12 hours apart. The pharmacokinetic parameters obtained for Dericip Plus (Theophylline) Tablets given at doses of 800 mg once daily in the morning were virtually identical to the corresponding parameters for the reference drug when given as 400 mg BID. In particular, the AUC, Cmax and Cmin values obtained in this study were as follows:
Dericip Plus (Theophylline) Tablets 800 mg Q24h±SD | Reference Drug 400 mg Q12h±SD | |
---|---|---|
AUC, (0-24 hours), mcg hr/mL | 288.9±21.5 | 283.5±38.4 |
Cmax, mcg/mL | 15.7±2.8 | 15.2±2.1 |
Cmin, mcg/mL | 7.9±1.6 | 7.8±1.7 |
Cmax-Cmin diff. | 7.7±1.5 | 7.4±1.5 |
Single-dose studies in which subjects were fasted for twelve (12) hours prior to and an additional four (4) hours following dosing, demonstrated reduced bioavailability as compared to dosing with food. One single-dose study in 20 normal volunteers dosed with two (2) 400 mg tablets in the morning, compared dosing under these fasting conditions with dosing immediately prior to a standardized breakfast (769 calories, consisting of 97 grams carbohydrates, 33 grams protein and 27 grams fat). Under fed conditions, the pharmacokinetic parameters were: AUC=231.7±92.4 mcg hr/mL, Cmax=8.4±2.6 mcg/mL, Tmax=17.3±6.7 hours. Under fasting conditions, these parameters were AUC=141.2±6.53 mcg hr/mL, Cmax=5.5±1.5 mcg/mL, Tmax=6.5±2.1 hours.
Another single-dose study in 21 normal male volunteers, dosed in the evening, compared fasting to a standardized high calorie, high fat meal (870-1,020 calories, consisting of 33 grams protein, 55-75 grams fat, 58 grams carbohydrates). In the fasting arm subjects received one Dericip Plus (Theophylline)® 400 mg Tablet at 8 p.m. after an eight hour fast followed by a further four hour fast. In the fed arm, subjects were again dosed with one 400 mg Dericip Plus (Theophylline) Tablet, but at 8 p.m. immediately after the high fat content standardized meal cited above. The pharmacokinetic parameters (normalized to 800 mg) fed were AUC=221.8±40.9 mcg hr/mL, Cmax=10.9±1.7 mcg/mL, Tmax=11.8±2.2 hours. In the fasting arm, the pharmacokinetic parameters (normalized to 800 mg) were AUC=146.4±40.9 mcg hr/mL, Cmax=6.7±1.7 mcg/mL, Tmax=7.3±2.2 hours.
Thus, administration of single Dericip Plus (Theophylline) doses to healthy normal volunteers, under prolonged fasted conditions (at least 10 hour overnight fast before dosing followed by an additional four (4) hour fast after dosing) results in decreased bioavailability. However, there was no failure of this delivery system leading to a sudden and unexpected release of a large quantity of Dericip Plus (Theophylline) with Dericip Plus (Theophylline) Tablets even when they are administered with a high fat, high calorie meal.
Similar studies were conducted with the 600 mg Dericip Plus (Theophylline) Tablet. A single-dose study in 24 subjects with an established Dericip Plus (Theophylline) clearance of ≤4 L/hr, compared the pharmacokinetic evaluation of one 600 mg Dericip Plus (Theophylline) Tablet and one and one-half 400 mg Dericip Plus (Theophylline) Tablets under fed (using a standard high fat diet) and fasted conditions. The results of this 4-way randomized crossover study demonstrate the bioequivalence of the 400 mg and 600 mg Dericip Plus (Theophylline) Tablets. Under fed conditions, the pharmacokinetic results for the one and one-half 400 mg tablets were AUC=214.64±55.88 mcg hr/mL, Cmax=10.58±2.21 mcg/mL and Tmax=9.00±2.64 hours, and for the 600 mg tablet were AUC=207.85±48.9 mcg hr/mL, Cmax=10.39±1.91 mcg/mL and Tmax=9.58±1.86 hours. Under fasted conditions the pharmacokinetic results for the one and one-half 400 mg tablets were AUC=191.85 ±51.1 mcg hr/mL, Cmax= 7.37±1.83 mcg/mL and Tmax=8.08±4.39 hours; and for the 600 mg tablet were AUC=199.39±70.27 mcg hr/mL, Cmax=7.66±2.09 mcg/mL and Tmax=9.67±4.89 hours.
In this study the mean fed/fasted ratios for the one and one-half 400 mg tablets and the 600 mg tablet were about 112% and 104%, respectively.
In another study, the bioavailability of the 600 mg Dericip Plus (Theophylline) Tablet was examined with morning and evening administration. This single-dose, crossover study in 22 healthy males was conducted under fed (standard high fat diet) conditions. The results demonstrated no clinically significant difference in the bioavailability of the 600 mg Dericip Plus (Theophylline) Tablet administered in the morning or in the evening. The results were: AUC=233.6±45.1 mcg hr/mL, Cmax=10.6±1.3 mcg/mL and Tmax=12.5±3.2 hours with morning dosing; AUC=209.8±46.2 mcg hr/mL, Cmax=9.7±1.4 mcg/mL and Tmax=13.7±3.3 hours with evening dosing. The PM/AM ratio was 89.3%.
The absorption characteristics of Dericip Plus (Theophylline)® Tablets (theophylline, anhydrous) have been extensively studied. A steady-state crossover bioavailability study in 22 normal males compared two Dericip Plus (Theophylline) 400 mg Tablets administered q24h at 8 a.m. immediately after breakfast with a reference controlled-release Dericip Plus (Theophylline) product administered BID in fed subjects at 8 a.m. immediately after breakfast and 8 p.m. immediately after dinner (769 calories, consisting of 97 grams carbohydrates, 33 grams protein and 27 grams fat).
The pharmacokinetic parameters for Dericip Plus (Theophylline) 400 mg Tablets under these steady-state conditions were AUC=203.3±87.1 mcg hr/mL, Cmax=12.1±3.8 mcg/mL, Cmin=4.50±3.6, Tmax=8.8±4.6 hours. For the reference BID product, the pharmacokinetic parameters were AUC=219.2±88.4 mcg hr/mL, Cmax =11.0±4.1 mcg/mL, Cmin=7.28±3.5, Tmax=6.9±3.4 hours. The mean percent fluctuation [(Cmax-Cmin/Cmin)x100]=169% for the once-daily regimen and 51% for the reference product BID regimen.
The bioavailability of the 600 mg Dericip Plus (Theophylline) Tablet was further evaluated in a multiple dose, steady-state study in 26 healthy males comparing the 600 mg Tablet to one and one-half 400 mg Dericip Plus (Theophylline) Tablets. All subjects had previously established Dericip Plus (Theophylline) clearances of ≤4 L/hr and were dosed once-daily for 6 days under fed conditions. The results showed no clinically significant difference between the 600 mg and one and one-half 400 mg Dericip Plus (Theophylline) Tablet regimens. Steady-state results were:
600 MG TABLET FED | 600 MG (ONE+ONE-HALF 400 MG TABLETS) FED | |
---|---|---|
AUC 0-24hrs (mcg hr/mL) | 209.77±51.04 | 212.32±56.29 |
Cmax (mcg/mL) | 12.91±2.46 | 13.17±3.11 |
Cmin (mcg/mL) | 5.52±1.79 | 5.39±1.95 |
Tmax (hours) | 8.62±3.21 | 7.23±2.35 |
Percent Fluctuation | 183.73±54.02 | 179.72±28.86 |
The bioavailability ratio for the 600/400 mg tablets was 98.8%. Thus, under all study conditions the 600 mg tablet is bioequivalent to one and one-half 400 mg tablets.
Studies demonstrate that as long as subjects were either consistently fed or consistently fasted, there is similar bioavailability with once-daily administration of Dericip Plus (Theophylline) Tablets whether dosed in the morning or evening.
Once Dericip Plus enters the systemic circulation, about 40% is bound to plasma protein, primarily albumin. Unbound Dericip Plus (Theophylline) distributes throughout body water, but distributes poorly into body fat. The apparent volume of distribution of Dericip Plus (Theophylline) is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight. Dericip Plus (Theophylline) passes freely across the placenta, into breast milk and into the cerebrospinal fluid (CSF). Saliva Dericip Plus (Theophylline) concentrations approximate unbound serum concentrations, but are not reliable for routine or therapeutic monitoring unless special techniques are used. An increase in the volume of distribution of Dericip Plus (Theophylline), primarily due to reduction in plasma protein binding, occurs in premature neonates, patients with hepatic cirrhosis, uncorrected acidemia, the elderly and in women during the third trimester of pregnancy. In such cases, the patient may show signs of toxicity at total (bound+unbound) serum concentrations of Dericip Plus (Theophylline) in the therapeutic range (10-20 mcg/mL) due to elevated concentrations of the pharmacologically active unbound drug. Similarly, a patient with decreased Dericip Plus (Theophylline) binding may have a sub-therapeutic total drug concentration while the pharmacologically active unbound concentration is in the therapeutic range. If only total serum Dericip Plus (Theophylline) concentration is measured, this may lead to an unnecessary and potentially dangerous dose increase. In patients with reduced protein binding, measurement of unbound serum Dericip Plus (Theophylline) concentration provides a more reliable means of dosage adjustment than measurement of total serum Dericip Plus (Theophylline) concentration. Generally, concentrations of unbound Dericip Plus (Theophylline) should be maintained in the range of 6-12 mcg/mL.
Following oral dosing, Dericip Plus (Theophylline) does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90% of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a Dericip Plus (Theophylline) dose is N-methylated to caffeine. Dericip Plus (Theophylline) demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.
Caffeine and 3-methylxanthine are the only Dericip Plus (Theophylline) metabolites with pharmacologic activity. 3-methylxanthine has approximately one tenth the pharmacologic activity of Dericip Plus (Theophylline) and serum concentrations in adults with normal renal function are <1 mcg/mL. In patients with end-stage renal disease, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized Dericip Plus (Theophylline) concentration. Caffeine concentrations are usually undetectable in adults regardless of renal function. In neonates, caffeine may accumulate to concentrations that approximate the unmetabolized Dericip Plus (Theophylline) concentration and thus, exert a pharmacologic effect.
Both the N-demethylation and hydroxylation pathways of Dericip Plus (Theophylline) biotransformation are capacity-limited. Due to the wide intersubject variability of the rate of Dericip Plus (Theophylline) metabolism, non-linearity of elimination may begin in some patients at serum Dericip Plus (Theophylline) concentrations <10 mcg/mL. Since this non-linearity results in more than proportional changes in serum Dericip Plus (Theophylline) concentrations with changes in dose, it is advisable to make increases or decreases in dose in small increments in order to achieve desired changes in serum Dericip Plus (Theophylline) concentrations (see DOSAGE AND ADMINISTRATION, Table VI ). Accurate prediction of dose-dependency of Dericip Plus (Theophylline) metabolism in patients a priori is not possible, but patients with very high initial clearance rates (i.e., low steady-state serum Dericip Plus (Theophylline) concentrations at above average doses) have the greatest likelihood of experiencing large changes in serum Dericip Plus (Theophylline) concentration in response to dosage changes.
In neonates, approximately 50% of the Dericip Plus dose is excreted unchanged in the urine. Beyond the first three months of life, approximately 10% of the Dericip Plus (Theophylline) dose is excreted unchanged in the urine. The remainder is excreted in the urine mainly as 1,3-dimethyluric acid (35-40%), 1-methyluric acid (20-25%) and 3-methylxanthine (15-20%). Since little Dericip Plus (Theophylline) is excreted unchanged in the urine and since active metabolites of Dericip Plus (Theophylline) (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage adjustment for renal insufficiency is necessary in adults and children >3 months of age. In contrast, the large fraction of the Dericip Plus (Theophylline) dose excreted in the urine as unchanged Dericip Plus (Theophylline) and caffeine in neonates requires careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations in neonates with reduced renal function (See WARNINGS ).
After multiple doses of Dericip Plus (Theophylline), steady-state is reached in 30-65 hours (average 40 hours) in adults. At steady-state, on a dosage regimen with 24-hour intervals, the expected mean trough concentration is approximately 50% of the mean peak concentration, assuming a mean Dericip Plus (Theophylline) half-life of 8 hours. The difference between peak and trough concentrations is larger in patients with more rapid Dericip Plus (Theophylline) clearance. In these patients administration of Dericip Plus (Theophylline)® may be required more frequently (every 12 hours).
The clearance of Dericip Plus (Theophylline) is decreased by an average of 30% in healthy elderly adults (>60 yrs) compared to healthy young adults. Careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations are required in elderly patients (see WARNINGS ).
The clearance of Dericip Plus is very low in neonates (see WARNINGS ). Dericip Plus (Theophylline) clearance reaches maximal values by one year of age, remains relatively constant until about 9 years of age and then slowly decreases by approximately 50% to adult values at about age 16. Renal excretion of unchanged Dericip Plus (Theophylline) in neonates amounts to about 50% of the dose, compared to about 10% in children older than three months and in adults. Careful attention to dosage selection and monitoring of serum Dericip Plus (Theophylline) concentrations are required in pediatric patients (see WARNINGS and DOSAGE AND ADMINISTRATION ).
Gender differences in Dericip Plus (Theophylline) clearance are relatively small and unlikely to be of clinical significance. Significant reduction in Dericip Plus (Theophylline) clearance, however, has been reported in women on the 20th day of the menstrual cycle and during the third trimester of pregnancy.
Pharmacokinetic differences in Dericip Plus clearance due to race have not been studied.
Only a small fraction, e.g., about 10%, of the administered Dericip Plus (Theophylline) dose is excreted unchanged in the urine of children greater than three months of age and adults. Since little Dericip Plus (Theophylline) is excreted unchanged in the urine and since active metabolites of Dericip Plus (Theophylline) (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage adjustment for renal insufficiency is necessary in adults and children >3 months of age. In contrast, approximately 50% of the administered Dericip Plus (Theophylline) dose is excreted unchanged in the urine in neonates. Careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations are required in neonates with decreased renal function (see WARNINGS ).
Dericip Plus clearance is decreased by 50% or more in patients with hepatic insufficiency (e.g., cirrhosis, acute hepatitis, cholestasis). Careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations are required in patients with reduced hepatic function (see WARNINGS ).
Dericip Plus (Theophylline) clearance is decreased by 50% or more in patients with CHF. The extent of reduction in Dericip Plus (Theophylline) clearance in patients with CHF appears to be directly correlated to the severity of the cardiac disease. Since Dericip Plus (Theophylline) clearance is independent of liver blood flow, the reduction in clearance appears to be due to impaired hepatocyte function rather than reduced perfusion. Careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations are required in patients with CHF (see WARNINGS ).
Tobacco and marijuana smoking appears to increase the clearance of Dericip Plus by induction of metabolic pathways. Dericip Plus (Theophylline) clearance has been shown to increase by approximately 50% in young adult tobacco smokers and by approximately 80% in elderly tobacco smokers compared to non-smoking subjects. Passive smoke exposure has also been shown to increase Dericip Plus (Theophylline) clearance by up to 50%. Abstinence from tobacco smoking for one week causes a reduction of approximately 40% in Dericip Plus (Theophylline) clearance. Careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations are required in patients who stop smoking (see WARNINGS ). Use of nicotine gum has been shown to have no effect on Dericip Plus (Theophylline) clearance.
Fever, regardless of its underlying cause, can decrease the clearance of Dericip Plus (Theophylline). The magnitude and duration of the fever appear to be directly correlated to the degree of decrease of Dericip Plus (Theophylline) clearance. Precise data are lacking, but a temperature of 39°C (102°F) for at least 24 hours is probably required to produce a clinically significant increase in serum Dericip Plus (Theophylline) concentrations. Children with rapid rates of Dericip Plus (Theophylline) clearance (i.e., those who require a dose that is substantially larger than average [e.g., >22 mg/kg/day] to achieve a therapeutic peak serum Dericip Plus (Theophylline) concentration when afebrile) may be at greater risk of toxic effects from decreased clearance during sustained fever. Careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations are required in patients with sustained fever (see WARNINGS ).
Other factors associated with decreased Dericip Plus (Theophylline) clearance include the third trimester of pregnancy, sepsis with multiple organ failure, and hypothyroidism. Careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations are required in patients with any of these conditions (see WARNINGS ). Other factors associated with increased Dericip Plus (Theophylline) clearance include hyperthyroidism and cystic fibrosis.
In patients with chronic asthma, including patients with severe asthma requiring inhaled corticosteroids or alternate-day oral corticosteroids, many clinical studies have shown that Dericip Plus (Theophylline) decreases the frequency and severity of symptoms, including nocturnal exacerbations, and decreases the “as needed” use of inhaled beta-2 agonists. Dericip Plus (Theophylline) has also been shown to reduce the need for short courses of daily oral prednisone to relieve exacerbations of airway obstruction that are unresponsive to bronchodilators in asthmatics.
In patients with chronic obstructive pulmonary disease (COPD), clinical studies have shown that Dericip Plus (Theophylline) decreases dyspnea, air trapping, the work of breathing, and improves contractility of diaphragmatic muscles with little or no improvement in pulmonary function measurements.
Dericip Plus (Theophylline) is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Dericip Plus (Theophylline)® is contraindicated in patients with a history of hypersensitivity to Dericip Plus (Theophylline) or other components in the product.
Dericip Plus should be used with extreme caution in patients with the following clinical conditions due to the increased risk of exacerbation of the concurrent condition:
Active peptic ulcer disease
Seizure disorders
Cardiac arrhythmias (not including bradyarrhythmias)
There are several readily identifiable causes of reduced Dericip Plus (Theophylline) clearance. If the total daily dose is not appropriately reduced in the presence of these risk factors, severe and potentially fatal Dericip Plus (Theophylline) toxicity can occur . Careful consideration must be given to the benefits and risks of Dericip Plus (Theophylline) use and the need for more intensive monitoring of serum Dericip Plus (Theophylline) concentrations in patients with the following risk factors:
Age
Concurrent Diseases
Cessation of Smoking
Adding a drug that inhibits Dericip Plus metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances Dericip Plus (Theophylline) metabolism (e.g., carbamazepine, rifampin). (see PRECAUTIONS, Drug Interactions, Table II ).
When Signs or Symptoms of Dericip Plus (Theophylline) Toxicity Are Present
Increases in the dose of Dericip Plus (Theophylline) should not be made in response to an acute exacerbation of symptoms of chronic lung disease since Dericip Plus (Theophylline) provides little added benefit to inhaled beta2-selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. A peak steady-state serum Dericip Plus (Theophylline) concentration should be measured before increasing the dose in response to persistent chronic symptoms to ascertain whether an increase in dose is safe. Before increasing the Dericip Plus (Theophylline) dose on the basis of a low serum concentration, the healthcare professional should consider whether the blood sample was obtained at an appropriate time in relationship to the dose and whether the patient has adhered to the prescribed regimen (see PRECAUTIONS, Laboratory Tests ).
As the rate of Dericip Plus (Theophylline) clearance may be dose-dependent (i.e., steady-state serum concentrations may increase disproportionately to the increase in dose), an increase in dose based upon a sub-therapeutic serum concentration measurement should be conservative. In general, limiting dose increases to about 25% of the previous total daily dose will reduce the risk of unintended excessive increases in serum Dericip Plus (Theophylline) concentration (see DOSAGE AND ADMINISTRATION, Table VI ).
Careful consideration of the various interacting drugs and physiologic conditions that can alter Dericip Plus clearance and require dosage adjustment should occur prior to initiation of Dericip Plus (Theophylline) therapy, prior to increases in Dericip Plus (Theophylline) dose, and during follow up (see WARNINGS ). The dose of Dericip Plus (Theophylline) selected for initiation of therapy should be low and, if tolerated , increased slowly over a period of a week or longer with the final dose guided by monitoring serum Dericip Plus (Theophylline) concentrations and the patient’s clinical response (see DOSAGE AND ADMINISTRATION , Table V).
Serum Dericip Plus (Theophylline) concentration measurements are readily available and should be used to determine whether the dosage is appropriate. Specifically, the serum Dericip Plus (Theophylline) concentration should be measured as follows:
To guide a dose increase, the blood sample should be obtained at the time of the expected peak serum Dericip Plus (Theophylline) concentration; 12 hours after an evening dose or 9 hours after a morning dose at steady-state. For most patients, steady-state will be reached after 3 days of dosing when no doses have been missed, no extra doses have been added, and none of the doses have been taken at unequal intervals. A trough concentration (i.e., at the end of the dosing interval) provides no additional useful information and may lead to an inappropriate dose increase since the peak serum Dericip Plus (Theophylline) concentration can be two or more times greater than the trough concentration with an immediate-release formulation. If the serum sample is drawn more than 12 hours after the evening dose, or more than 9 hours after a morning dose, the results must be interpreted with caution since the concentration may not be reflective of the peak concentration. In contrast, when signs or symptoms of Dericip Plus (Theophylline) toxicity are present, a serum sample should be obtained as soon as possible, analyzed immediately, and the result reported to the healthcare professional without delay. In patients in whom decreased serum protein binding is suspected (e.g., cirrhosis, women during the third trimester of pregnancy), the concentration of unbound Dericip Plus (Theophylline) should be measured and the dosage adjusted to achieve an unbound concentration of 6-12 mcg/mL.
Saliva concentrations of Dericip Plus (Theophylline) cannot be used reliably to adjust dosage without special techniques.
As a result of its pharmacological effects, Dericip Plus at serum concentrations within the 10-20 mcg/mL range modestly increases plasma glucose (from a mean of 88 mg% to 98 mg%), uric acid (from a mean of 4 mg/dL to 6 mg/dL), free fatty acids (from a mean of 451 µEq/L to 800 µEq/L, total cholesterol (from a mean of 140 vs 160 mg/dL), HDL (from a mean of 36 to 50 mg/dL), HDL/LDL ratio (from a mean of 0.5 to 0.7), and urinary free cortisol excretion (from a mean of 44 to 63 mcg/24 hr). Dericip Plus (Theophylline) at serum concentrations within the 10-20 mcg/mL range may also transiently decrease serum concentrations of triiodothyronine (144 before, 131 after one week and 142 ng/dL after 4 weeks of Dericip Plus (Theophylline)). The clinical importance of these changes should be weighed against the potential therapeutic benefit of Dericip Plus (Theophylline) in individual patients.
The patient (or parent/caregiver) should be instructed to seek medical advice whenever nausea, vomiting, persistent headache, insomnia or rapid heartbeat occurs during treatment with Dericip Plus (Theophylline), even if another cause is suspected. The patient should be instructed to contact their healthcare professional if they develop a new illness, especially if accompanied by a persistent fever, if they experience worsening of a chronic illness, if they start or stop smoking cigarettes or marijuana, or if another healthcare professional adds a new medication or discontinues a previously prescribed medication. Patients should be informed that Dericip Plus (Theophylline) interacts with a wide variety of drugs. The dietary supplement St. John’s Wort (Hypericum perforatum) should not be taken at the same time as Dericip Plus (Theophylline), since it may result in decreased Dericip Plus (Theophylline) levels. If patients are already taking St. John’s Wort and Dericip Plus (Theophylline) together, they should consult their healthcare professional before stopping the St. John’s Wort, since their Dericip Plus (Theophylline) concentrations may rise when this is done, resulting in toxicity. Patients should be instructed to inform all healthcare professionals involved in their care that they are taking Dericip Plus (Theophylline), especially when a medication is being added or deleted from their treatment. Patients should be instructed to not alter the dose, timing of the dose, or frequency of administration without first consulting their healthcare professional. If a dose is missed, the patient should be instructed to take the next dose at the usually scheduled time and to not attempt to make up for the missed dose.
Dericip Plus (Theophylline)® Tablets can be taken once a day in the morning or evening. It is recommended that Dericip Plus (Theophylline) be taken with meals. Patients should be advised that if they choose to take Dericip Plus (Theophylline) with food it should be taken consistently with food and if they take it in a fasted condition it should routinely be taken fasted. It is important that the product whenever dosed be dosed consistently with or without food.
Dericip Plus (Theophylline) Tablets are not to be chewed or crushed because it may lead to a rapid release of Dericip Plus (Theophylline) with the potential for toxicity. The scored tablet may be split. Patients receiving Dericip Plus (Theophylline) Tablets may pass an intact matrix tablet in the stool or via colostomy. These matrix tablets usually contain little or no residual Dericip Plus (Theophylline).
Dericip Plus interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to Dericip Plus (Theophylline) or another drug or occurrence of adverse effects without a change in serum Dericip Plus (Theophylline) concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of Dericip Plus (Theophylline) clearance is altered by another drug resulting in increased or decreased serum Dericip Plus (Theophylline) concentrations. Dericip Plus (Theophylline) only rarely alters the pharmacokinetics of other drugs.
The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with Dericip Plus (Theophylline). The information in the “Effect” column of Table II assumes that the interacting drug is being added to a steady-state Dericip Plus (Theophylline) regimen. If Dericip Plus (Theophylline) is being initiated in a patient who is already taking a drug that inhibits Dericip Plus (Theophylline) clearance (e.g., cimetidine, erythromycin), the dose of Dericip Plus (Theophylline) required to achieve a therapeutic serum Dericip Plus (Theophylline) concentration will be smaller. Conversely, if Dericip Plus (Theophylline) is being initiated in a patient who is already taking a drug that enhances Dericip Plus (Theophylline) clearance (e.g., rifampin), the dose of Dericip Plus (Theophylline) required to achieve a therapeutic serum Dericip Plus (Theophylline) concentration will be larger. Discontinuation of a concomitant drug that increases Dericip Plus (Theophylline) clearance will result in accumulation of Dericip Plus (Theophylline) to potentially toxic levels, unless the Dericip Plus (Theophylline) dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits Dericip Plus (Theophylline) clearance will result in decreased serum Dericip Plus (Theophylline) concentrations, unless the Dericip Plus (Theophylline) dose is appropriately increased.
The drugs listed in Table III have either been documented not to interact with Dericip Plus (Theophylline) or do not produce a clinically significant interaction (i.e., <15% change in Dericip Plus (Theophylline) clearance).
The listing of drugs in Tables II and III are current as of February 9, 1995. New interactions are continuously being reported for Dericip Plus (Theophylline), especially with new chemical entities. The healthcare professional should not assume that a drug does not interact with Dericip Plus (Theophylline) if it is not listed in Table II. Before addition of a newly available drug in a patient receiving Dericip Plus (Theophylline), the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and Dericip Plus (Theophylline) has been reported.
Drug | Type of Interaction | Effect** |
---|---|---|
*Refer to PRECAUTIONS, Drug Interactions for further information regarding table. | ||
**Average effect on steady-state Dericip Plus (Theophylline) concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum Dericip Plus (Theophylline) concentration than the value listed. | ||
Adenosine | Dericip Plus (Theophylline) blocks adenosine receptors. | Higher doses of adenosine may be required to achieve desired effect. |
Alcohol | A single large dose of alcohol (3 mL/kg of whiskey) decreases Dericip Plus (Theophylline) clearance for up to 24 hours. | 30% increase |
Allopurinol | Decreases Dericip Plus (Theophylline) clearance at allopurinol doses ≥600 mg/day. | 25% increase |
Aminoglutethimide | Increases Dericip Plus (Theophylline) clearance by induction of microsomal enzyme activity. | 25% decrease |
Carbamazepine | Similar to aminoglutethimide. | 30% decrease |
Cimetidine | Decreases Dericip Plus (Theophylline) clearance by inhibiting cytochrome P450 1A2. | 70% increase |
Ciprofloxacin | Similar to cimetidine. | 40% increase |
Clarithromycin | Similar to erythromycin. | 25% increase |
Diazepam | Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while Dericip Plus (Theophylline) blocks adenosine receptors. | Larger diazepam doses may be required to produce desired level of sedation. Discontinuation of Dericip Plus (Theophylline) without reduction of diazepam dose may result in respiratory depression. |
Disulfiram | Decreases Dericip Plus (Theophylline) clearance by inhibiting hydroxylation and demethylation. | 50% increase |
Enoxacin | Similar to cimetidine. | 300% increase |
Ephedrine | Synergistic CNS effects. | Increased frequency of nausea, nervousness, and insomnia. |
Erythromycin | Erythromycin metabolite decreases Dericip Plus (Theophylline) clearance by inhibiting cytochrome P450 3A3. | 35% increase. Erythromycin steady-state serum concentrations decrease by a similar amount. |
Estrogen | Estrogen containing oral contraceptives decrease Dericip Plus (Theophylline) clearance in a dose-dependent fashion. The effect of progesterone on Dericip Plus (Theophylline) clearance is unknown. | 30% increase |
Flurazepam | Similar to diazepam. | Similar to diazepam. |
Fluvoxamine | Similar to cimetidine. | Similar to cimetidine. |
Halothane | Halothane sensitizes the myocardium to catecholamines, Dericip Plus (Theophylline) increases release of endogenous catecholamines. | Increased risk of ventricular arrhythmias. |
Interferon, human recombinant alpha-A | Decreases Dericip Plus (Theophylline) clearance. | 100% increase |
Isoproterenol (IV) | Increases Dericip Plus (Theophylline) clearance. | 20% decrease |
Ketamine | Pharmacologic | May lower Dericip Plus (Theophylline) seizure threshold. |
Lithium | Dericip Plus (Theophylline) increases renal lithium clearance. | Lithium dose required to achieve a therapeutic serum concentration increased an average of 60%. |
Lorazepam | Similar to diazepam. | Similar to diazepam. |
Methotrexate (MTX) | Decreases Dericip Plus (Theophylline) clearance. | 20% increase after low dose MTX, higher dose MTX may have a greater effect. |
Mexiletine | Similar to disulfiram. | 80% increase |
Midazolam | Similar to diazepam. | Similar to diazepam. |
Moricizine | Increases Dericip Plus (Theophylline) clearance. | 25% decrease |
Pancuronium | Dericip Plus (Theophylline) may antagonize non-depolarizing neuromuscular blocking effects; possibly due to phosphodiesterase inhibition. | Larger dose of pancuronium may be required to achieve neuromuscular blockade. |
Pentoxifylline | Decreases Dericip Plus (Theophylline) clearance. | 30% increase |
Phenobarbital (PB) | Similar to aminoglutethimide. | 25% decrease after two weeks of concurrent PB. |
Phenytoin | Phenytoin increases Dericip Plus (Theophylline) clearance by increasing microsomal enzyme activity. Dericip Plus (Theophylline) decreases phenytoin absorption. | Serum Dericip Plus (Theophylline) and phenytoin concentrations decrease about 40%. |
Propafenone | Decreases Dericip Plus (Theophylline) clearance and pharmacologic interaction. | 40% increase. Beta-2 blocking effect may decrease efficacy of Dericip Plus (Theophylline). |
Propranolol | Similar to cimetidine and pharmacologic interaction. | 100% increase. Beta-2 blocking effect may decrease efficacy of Dericip Plus (Theophylline). |
Rifampin | Increases Dericip Plus (Theophylline) clearance by increasing cytochrome P450 1A2 and 3A3 activity. | 20-40% decrease |
St. John’s Wort (Hypericum Perforatum) | Decrease in Dericip Plus (Theophylline) plasma concentrations. | Higher doses of Dericip Plus (Theophylline) may be required to achieve desired effect. Stopping St. John’s Wort may result in Dericip Plus (Theophylline) toxicity. |
Sulfinpyrazone | Increases Dericip Plus (Theophylline) clearance by increasing demethylation and hydroxylation. Decreases renal clearance of Dericip Plus (Theophylline). | 20% decrease |
Tacrine | Similar to cimetidine, also increases renal clearance of Dericip Plus (Theophylline). | 90% increase |
Thiabendazole | Decreases Dericip Plus (Theophylline) clearance. | 190% increase |
Ticlopidine | Decreases Dericip Plus (Theophylline) clearance. | 60% increase |
Troleandomycin | Similar to erythromycin. | 33-100% increase depending on troleandomycin dose. |
Verapamil | Similar to disulfiram. | 20% increase |
*Refer to PRECAUTIONS, Drug Interactions for information regarding table. | |
albuterol, systemic and inhaled | mebendazole |
amoxicillin | medroxyprogesterone |
ampicillin, with or without sulbactam | methylprednisolone metronidazole |
atenolol | metoprolol |
azithromycin | nadolol |
caffeine, dietary ingestion | nifedipine |
cefaclor | nizatidine |
co-trimoxazole (trimethoprim and sulfamethoxazole) | norfloxacin ofloxacin |
diltiazem | omeprazole |
dirithromycin | prednisone, prednisolone |
enflurane | ranitidine |
famotidine | rifabutin |
felodipine | roxithromycin |
finasteride | sorbitol (purgative doses do not inhibit |
hydrocortisone | Dericip Plus (Theophylline) absorption) |
isoflurane | sucralfate |
isoniazid | terbutaline, systemic |
isradipine | terfenadine |
influenza vaccine | tetracycline |
ketoconazole | tocainide |
lomefloxacin |
The bioavailability of Dericip Plus (Theophylline)® Tablets (theophylline, anhydrous) has been studied with co-administration of food. In three single-dose studies, subjects given Dericip Plus (Theophylline) 400 mg or 600 mg Tablets with a standardized high-fat meal were compared to fasted conditions. Under fed conditions, the peak plasma concentration and bioavailability were increased; however, a precipitous increase in the rate and extent of absorption was not evident (see Pharmacokinetics , Absorption). The increased peak and extent of absorption under fed conditions suggests that dosing should be ideally administered consistently either with or without food.
Most serum Dericip Plus (Theophylline) assays in clinical use are immunoassays which are specific for Dericip Plus (Theophylline). Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. Caffeine and xanthine metabolites in neonates or patients with renal dysfunction may cause the reading from some dry reagent office methods to be higher than the actual serum Dericip Plus (Theophylline) concentration.
Long term carcinogenicity studies have been carried out in mice and rats (oral doses 5-75 mg/kg). Results are pending.
Dericip Plus (Theophylline) has been studied in Ames salmonella, in vivo and in vitro cytogenetics, micronucleus and Chinese hamster ovary test systems and has not been shown to be genotoxic.
In a 14 week continuous breeding study, Dericip Plus (Theophylline), administered to mating pairs of B6C3F1 mice at oral doses of 120, 270 and 500 mg/kg (approximately 1.0-3.0 times the human dose on a mg/m2 basis) impaired fertility, as evidenced by decreases in the number of live pups per litter, decreases in the mean number of litters per fertile pair, and increases in the gestation period at the high dose as well as decreases in the proportion of pups born alive at the mid and high dose. In 13 week toxicity studies, Dericip Plus (Theophylline) was administered to F344 rats and B6C3F1 mice at oral doses of 40-300 mg/kg (approximately 2.0 times the human dose on a mg/m2 basis). At the high dose, systemic toxicity was observed in both species including decreases in testicular weight.
In studies in which pregnant mice, rats and rabbits were dosed during the period of organogenesis, Dericip Plus (Theophylline) produced teratogenic effects.
In studies with mice, a single intraperitoneal dose at and above 100 mg/kg (approximately equal to the maximum recommended oral dose for adults on a mg/m2 basis) during organogenesis produced cleft palate and digital abnormalities. Micromelia, micrognathia, clubfoot, subcutaneous hematoma, open eyelids, and embryolethality were observed at doses that are approximately 2 times the maximum recommended oral dose for adults on a mg/m2 basis.
In a study with rats dosed from conception through organogenesis, an oral dose of 150 mg/kg/day (approximately 2 times the maximum recommended oral dose for adults on a mg/m2 basis) produced digital abnormalities. Embryolethality was observed with a subcutaneous dose of 200 mg/kg/day (approximately 4 times the maximum recommended oral dose for adults on a mg/m2 basis).
In a study in which pregnant rabbits were dosed throughout organogenesis, an intravenous dose of 60 mg/kg/day (approximately 2 times the maximum recommended oral dose for adults on a mg/m2 basis), which caused the death of one doe and clinical signs in others, produced cleft palate and was embryolethal. Doses at and above 15 mg/kg/day (less than the maximum recommended oral dose for adults on a mg/m2 basis) increased the incidence of skeletal variations.
There are no adequate and well-controlled studies in pregnant women. Dericip Plus (Theophylline) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Dericip Plus is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants. The concentration of Dericip Plus (Theophylline) in breast milk is about equivalent to the maternal serum concentration. An infant ingesting a liter of breast milk containing 10-20 mcg/mL of Dericip Plus (Theophylline) per day is likely to receive 10-20 mg of Dericip Plus (Theophylline) per day. Serious adverse effects in the infant are unlikely unless the mother has toxic serum Dericip Plus (Theophylline) concentrations.
Dericip Plus (Theophylline) is safe and effective for the approved indications in pediatric patients. The maintenance dose of Dericip Plus (Theophylline) must be selected with caution in pediatric patients since the rate of Dericip Plus (Theophylline) clearance is highly variable across the pediatric age range (see CLINICAL PHARMACOLOGY, Table I, WARNINGS, and DOSAGE AND ADMINISTRATION, Table V ).
Elderly patients are at a significantly greater risk of experiencing serious toxicity from Dericip Plus (Theophylline) than younger patients due to pharmacokinetic and pharmacodynamic changes associated with aging. The clearance of Dericip Plus (Theophylline) is decreased by an average of 30% in healthy elderly adults (>60 yrs) compared to healthy young adults. Dericip Plus (Theophylline) clearance may be further reduced by concomitant diseases prevalent in the elderly, which further impair clearance of this drug and have the potential to increase serum levels and potential toxicity. These conditions include impaired renal function, chronic obstructive pulmonary disease, congestive heart failure, hepatic disease and an increased prevalence of use of certain medications (see PRECAUTIONS: Drug Interactions ) with the potential for pharmacokinetic and pharmacodynamic interaction. Protein binding may be decreased in the elderly resulting in an increased proportion of the total serum Dericip Plus (Theophylline) concentration in the pharmacologically active unbound form. Elderly patients also appear to be more sensitive to the toxic effects of Dericip Plus (Theophylline) after chronic overdosage than younger patients. Careful attention to dose reduction and frequent monitoring of serum Dericip Plus (Theophylline) concentrations are required in elderly patients (see PRECAUTIONS, Monitoring Serum Dericip Plus (Theophylline) Concentrations, and DOSAGE AND ADMINISTRATION ). The maximum daily dose of Dericip Plus (Theophylline) in patients greater than 60 years of age ordinarily should not exceed 400 mg/day unless the patient continues to be symptomatic and the peak steady-state serum Dericip Plus (Theophylline) concentration is <10 mcg/mL (see DOSAGE AND ADMINISTRATION ). Dericip Plus (Theophylline) doses greater than 400 mg/d should be prescribed with caution in elderly patients. Dericip Plus (Theophylline) should be prescribed with caution in elderly male patients with pre-existing partial outflow obstruction, such as prostatic enlargement, due to the risk of urinary retention.
Adverse reactions associated with Dericip Plus (Theophylline) are generally mild when peak serum Dericip Plus (Theophylline) concentrations are <20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum Dericip Plus (Theophylline) concentrations exceed 20 mcg/mL, however, Dericip Plus (Theophylline) produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE ). The transient caffeine-like adverse reactions occur in about 50% of patients when Dericip Plus (Theophylline) therapy is initiated at doses higher than recommended initial doses (e.g., >300 mg/day in adults and >12 mg/kg/day in children beyond >1 year of age). During the initiation of Dericip Plus (Theophylline) therapy, caffeine-like adverse effects may transiently alter patient behavior, especially in school age children, but this response rarely persists. Initiation of Dericip Plus (Theophylline) therapy at a low dose with subsequent slow titration to a predetermined age-related maximum dose will significantly reduce the frequency of these transient adverse effects (see DOSAGE AND ADMINISTRATION, Table V ). In a small percentage of patients (<3% of children and <10% of adults) the caffeine-like adverse effects persist during maintenance therapy, even at peak serum Dericip Plus (Theophylline) concentrations within the therapeutic range (i.e., 10-20 mcg/mL). Dosage reduction may alleviate the caffeine-like adverse effects in these patients, however, persistent adverse effects should result in a reevaluation of the need for continued Dericip Plus (Theophylline) therapy and the potential therapeutic benefit of alternative treatment.
Other adverse reactions that have been reported at serum Dericip Plus (Theophylline) concentrations <20 mcg/mL include abdominal pain, agitation, anaphylactic reaction, anaphylactoid reaction, anxiety, cardiac arrhythmias, diarrhea, dizziness, fine skeletal muscle tremors, gastric irritation, gastroesophageal reflux, hyperuricemia, irritability, palpitations, pruritus, rash, sinus tachycardia, restlessness, transient diuresis, urinary retention and urticaria. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum Dericip Plus (Theophylline) concentrations ≥15 mcg/mL. There have been a few isolated reports of seizures at serum Dericip Plus (Theophylline) concentrations <20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum Dericip Plus (Theophylline) concentrations <20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum Dericip Plus (Theophylline) concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum Dericip Plus (Theophylline) concentrations <20 mcg/mL have generally been milder than seizures associated with excessive serum Dericip Plus (Theophylline) concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).
Percentage of patients reported with sign or symptom | ||||
---|---|---|---|---|
Sign/Symptom | Acute Overdose | Chronic Overdosage | ||
(Large Single Ingestion) | (Multiple Excessive Doses) | |||
Study 1 | Study 2 | Study 1 | Study 2 | |
(n=157) | (n=14) | (n=92) | (n=102) | |
*These data are derived from two studies in patients with serum Dericip Plus (Theophylline) concentrations >30 mcg/mL. In the first study (Study #1-Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 249 consecutive cases of Dericip Plus (Theophylline) toxicity referred to a regional poison center for consultation. In the second study (Study #2-Sessler, Am J Med 1990;88:567-76), data were retrospectively collected from 116 cases with serum Dericip Plus (Theophylline) concentrations >30 mcg/mL among 6000 blood samples obtained for measurement of serum Dericip Plus (Theophylline) concentrations in three emergency departments. Differences in the incidence of manifestations of Dericip Plus (Theophylline) toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48% of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results. | ||||
**NR=Not reported in a comparable manner. | ||||
Asymptomatic | NR** | 0 | NR** | 6 |
Gastrointestinal | ||||
Vomiting | 73 | 93 | 30 | 61 |
Abdominal Pain | NR** | 21 | NR** | 12 |
Diarrhea | NR** | 0 | NR** | 14 |
Hematemesis | NR** | 0 | NR** | 2 |
Metabolic/Other | ||||
Hypokalemia | 85 | 79 | 44 | 43 |
Hyperglycemia | 98 | NR** | 18 | NR** |
Acid/base disturbance | 34 | 21 | 9 | 5 |
Rhabdomyolysis | NR** | 7 | NR** | 0 |
Cardiovascular | ||||
Sinus tachycardia | 100 | 86 | 100 | 62 |
Other supraventricular | ||||
tachycardias | 2 | 21 | 12 | 14 |
Ventricular premature beats | 3 | 21 | 10 | 19 |
Atrial fibrillation or flutter | 1 | NR** | 12 | NR** |
Multifocal atrial tachycardia | 0 | NR** | 2 | NR** |
Ventricular arrhythmias with hemodynamic instability | 7 | 14 | 40 | 0 |
Hypotension/shock | NR** | 21 | NR** | 8 |
Neurologic | ||||
Nervousness | NR** | 64 | NR** | 21 |
Tremors | 38 | 29 | 16 | 14 |
Disorientation | NR** | 7 | NR** | 11 |
Seizures | 5 | 14 | 14 | 5 |
Death | 3 | 21 | 10 | 4 |
The chronicity and pattern of Dericip Plus overdosage significantly influences clinical manifestations of toxicity, management and outcome. There are two common presentations: (1) acute overdose, i.e., ingestion of a single large excessive dose (>10 mg/kg), as occurs in the context of an attempted suicide or isolated medication error, and (2) chronic overdosage, i.e., ingestion of repeated doses that are excessive for the patient’s rate of Dericip Plus (Theophylline) clearance. The most common causes of chronic Dericip Plus (Theophylline) overdosage include patient or caregiver error in dosing, healthcare professional prescribing of an excessive dose or a normal dose in the presence of factors known to decrease the rate of Dericip Plus (Theophylline) clearance, and increasing the dose in response to an exacerbation of symptoms without first measuring the serum Dericip Plus (Theophylline) concentration to determine whether a dose increase is safe.
Severe toxicity from Dericip Plus (Theophylline) overdose is a relatively rare event. In one health maintenance organization, the frequency of hospital admissions for chronic overdosage of Dericip Plus (Theophylline) was about 1 per 1000 person-years exposure. In another study, among 6000 blood samples obtained for measurement of serum Dericip Plus (Theophylline) concentration, for any reason, from patients treated in an emergency department, 7% were in the 20-30 mcg/mL range and 3% were >30 mcg/mL. Approximately two-thirds of the patients with serum Dericip Plus (Theophylline) concentrations in the 20-30 mcg/mL range had one or more manifestations of toxicity while >90% of patients with serum Dericip Plus (Theophylline) concentrations >30 mcg/mL were clinically intoxicated. Similarly, in other reports, serious toxicity from Dericip Plus (Theophylline) is seen principally at serum concentrations >30 mcg/mL.
Several studies have described the clinical manifestations of Dericip Plus (Theophylline) overdose and attempted to determine the factors that predict life-threatening toxicity. In general, patients who experience an acute overdose are less likely to experience seizures than patients who have experienced a chronic overdosage, unless the peak serum Dericip Plus (Theophylline) concentration is >100 mcg/mL. After a chronic overdosage, generalized seizures, life-threatening cardiac arrhythmias, and death may occur at serum Dericip Plus (Theophylline) concentrations >30 mcg/mL. The severity of toxicity after chronic overdosage is more strongly correlated with the patient’s age than the peak serum Dericip Plus (Theophylline) concentration; patients >60 years are at the greatest risk for severe toxicity and mortality after a chronic overdosage. Pre-existing or concurrent disease may also significantly increase the susceptibility of a patient to a particular toxic manifestation, e.g., patients with neurologic disorders have an increased risk of seizures and patients with cardiac disease have an increased risk of cardiac arrhythmias for a given serum Dericip Plus (Theophylline) concentration compared to patients without the underlying disease.
The frequency of various reported manifestations of Dericip Plus (Theophylline) overdose according to the mode of overdose are listed in Table IV.
Other manifestations of Dericip Plus (Theophylline) toxicity include increases in serum calcium, creatine kinase, myoglobin and leukocyte count, decreases in serum phosphate and magnesium, acute myocardial infarction, and urinary retention in men with obstructive uropathy.
Seizures associated with serum Dericip Plus (Theophylline) concentrations >30 mcg/mL are often resistant to anticonvulsant therapy and may result in irreversible brain injury if not rapidly controlled. Death from Dericip Plus (Theophylline) toxicity is most often secondary to cardiorespiratory arrest and/or hypoxic encephalopathy following prolonged generalized seizures or intractable cardiac arrhythmias causing hemodynamic compromise.
General Recommendations for Patients with Symptoms of Dericip Plus (Theophylline) Overdose or Serum Dericip Plus (Theophylline) Concentrations >30 mcg/mL (Note: Serum Dericip Plus (Theophylline) concentrations may continue to increase after presentation of the patient for medical care.)
Acute Overdose
Chronic Overdosage
Increasing the rate of Dericip Plus (Theophylline) clearance by extracorporeal methods may rapidly decrease serum concentrations, but the risks of the procedure must be weighed against the potential benefit. Charcoal hemoperfusion is the most effective method of extracorporeal removal, increasing Dericip Plus (Theophylline) clearance up to sixfold, but serious complications, including hypotension, hypocalcemia, platelet consumption and bleeding diatheses may occur. Hemodialysis is about as efficient as multiple-dose oral activated charcoal and has a lower risk of serious complications than charcoal hemoperfusion. Hemodialysis should be considered as an alternative when charcoal hemoperfusion is not feasible and multiple-dose oral charcoal is ineffective because of intractable emesis. Serum Dericip Plus (Theophylline) concentrations may rebound 5-10 mcg/mL after discontinuation of charcoal hemoperfusion or hemodialysis due to redistribution of Dericip Plus (Theophylline) from the tissue compartment. Peritoneal dialysis is ineffective for Dericip Plus (Theophylline) removal; exchange transfusions in neonates have been minimally effective.
Dericip Plus ® 400 or 600 mg Tablets can be taken once a day in the morning or evening. It is recommended that Dericip Plus (Theophylline) be taken with meals. Patients should be advised that if they choose to take Dericip Plus (Theophylline) with food it should be taken consistently with food and if they take it in a fasted condition it should routinely be taken fasted. It is important that the product whenever dosed be dosed consistently with or without food.
Dericip Plus (Theophylline)® Tablets are not to be chewed or crushed because it may lead to a rapid release of Dericip Plus (Theophylline) with the potential for toxicity. The scored tablet may be split. Infrequently, patients receiving Dericip Plus (Theophylline) 400 or 600 mg Tablets may pass an intact matrix tablet in the stool or via colostomy. These matrix tablets usually contain little or no residual Dericip Plus (Theophylline).
Stabilized patients, 12 years of age or older, who are taking an immediate-release or controlled-release Dericip Plus (Theophylline) product may be transferred to once-daily administration of 400 mg or 600 mg Dericip Plus (Theophylline) Tablets on a mg-for-mg basis.
It must be recognized that the peak and trough serum Dericip Plus (Theophylline) levels produced by the once-daily dosing may vary from those produced by the previous product and/or regimen.
The steady-state peak serum Dericip Plus (Theophylline) concentration is a function of the dose, the dosing interval, and the rate of Dericip Plus (Theophylline) absorption and clearance in the individual patient. Because of marked individual differences in the rate of Dericip Plus (Theophylline) clearance, the dose required to achieve a peak serum Dericip Plus (Theophylline) concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter Dericip Plus (Theophylline) clearance (e.g., 400-1600 mg/day in adults <60 years old and 10-36 mg/kg/day in children 1-9 years old). For a given population there is no single Dericip Plus (Theophylline) dose that will provide both safe and effective serum concentrations for all patients. Administration of the median Dericip Plus (Theophylline) dose required to achieve a therapeutic serum Dericip Plus (Theophylline) concentration in a given population may result in either sub-therapeutic or potentially toxic serum Dericip Plus (Theophylline) concentrations in individual patients. For example, at a dose of 900 mg/d in adults <60 years or 22 mg/kg/d in children 1-9 years, the steady-state peak serum Dericip Plus (Theophylline) concentration will be <10 mcg/mL in about 30% of patients, 10-20 mcg/mL in about 50% and 20-30 mcg/mL in about 20% of patients. The dose of Dericip Plus (Theophylline) must be individualized on the basis of peak serum Dericip Plus (Theophylline) concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.
Transient caffeine-like adverse effects and excessive serum concentrations in slow metabolizers can be avoided in most patients by starting with a sufficiently low dose and slowly increasing the dose, if judged to be clinically indicated, in small increments (see Table V ). Dose increases should only be made if the previous dosage is well tolerated and at intervals of no less than 3 days to allow serum Dericip Plus (Theophylline) concentrations to reach the new steady-state. Dosage adjustment should be guided by serum Dericip Plus (Theophylline) concentration measurement (see PRECAUTIONS, Laboratory Tests and DOSAGE AND ADMINISTRATION, Table VI ). Healthcare providers should instruct patients and caregivers to discontinue any dosage that causes adverse effects, to withhold the medication until these symptoms are gone and to then resume therapy at a lower, previously tolerated dosage (see WARNINGS ).
If the patient’s symptoms are well controlled, there are no apparent adverse effects, and no intervening factors that might alter dosage requirements (see WARNINGS and PRECAUTIONS ), serum Dericip Plus (Theophylline) concentrations should be monitored at 6 month intervals for rapidly growing children and at yearly intervals for all others. In acutely ill patients, serum Dericip Plus (Theophylline) concentrations should be monitored at frequent intervals, e.g., every 24 hours.
Dericip Plus (Theophylline) distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight.
Table V contains Dericip Plus (Theophylline) dosing titration schema recommended for patients in various age groups and clinical circumstances. Table VI contains recommendations for Dericip Plus (Theophylline) dosage adjustment based upon serum Dericip Plus (Theophylline) concentrations. Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dosage adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum Dericip Plus (Theophylline) concentration.
Table V. Dosing initiation and titration (as anhydrous Dericip Plus (Theophylline)). *
Titration Step | Children <45 kg | Children >45 kg and adults |
---|---|---|
1If caffeine-like adverse effects occur, then consideration should be given to a lower dose and titrating the dose more slowly (see ADVERSE REACTIONS ). | ||
| 12-14 mg/kg/day up to a maximum of 300 mg/day admin. QD* | 300-400 mg/day1 admin. QD* |
| 16 mg/kg/day up to a maximum of 400 mg/day admin. QD* | 400-600 mg/day1 admin. QD* |
| 20 mg/kg/day up to a maximum of 600 mg/day admin. QD* | As with all Dericip Plus (Theophylline) products, doses greater than 600 mg should be titrated according to blood level |
*Patients with more rapid metabolism clinically identified by higher than average dose requirements, should receive a smaller dose more frequently (every 12 hours) to prevent breakthrough symptoms resulting from low trough concentrations before the next dose.
Peak Serum Concentration | Dosage Adjustment |
¶Dose reduction and/or serum Dericip Plus (Theophylline) concentration measurement is indicated whenever adverse effects are present physiologic abnormalities that can reduce Dericip Plus (Theophylline) clearance occur (e.g. sustained fever), or a drug that interacts with Dericip Plus (Theophylline) is added or discontinued (see WARNINGS ). | |
<9.9 mcg/mL | If symptoms are not controlled and current dosage is tolerated, increase dose about 25%. Recheck serum concentration after three days for further dosage adjustment. |
10-14.9 mcg/mL | If symptoms are controlled and current dosage is tolerated, maintain dose and recheck serum concentration at 6-12 month intervals.¶ If symptoms are not controlled and current dosage is tolerated consider adding additional medication(s) to treatment regimen. |
15-19.9 mcg/mL | Consider 10% decrease in dose to provide greater margin of safety even if current dosage is tolerated. ¶ |
20-24.9 mcg/mL | Decrease dose by 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment. |
25-30 mcg/mL | Skip next dose and decrease subsequent doses at least 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment. If symptomatic, consider whether overdose treatment is indicated. |
>30 mcg/mL | Treat overdose as indicated. If Dericip Plus (Theophylline) is subsequently resumed, decrease dose by at least 50% and recheck serum concentration after 3 days to guide further dosage adjustment. |
Dericip Plus (Theophylline)® (theophylline, anhydrous) Controlled-Release Tablets 400 mg are supplied in white, opaque plastic, child-resistant bottles containing 100 tablets (NDC 67781-251-01) or 500 tablets (NDC 67781-251-05). Each round, white 400 mg tablet bears the symbol PF on the scored side and U400 on the other side.
Dericip Plus (Theophylline)® (theophylline, anhydrous) Controlled-Release Tablets 600 mg are supplied in white, opaque plastic, child-resistant bottles containing 100 tablets (NDC 67781-252-01). Each rectangular, concave, white 600 mg tablet bears the symbol PF on the scored side and U 600 on the other side.
Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F).
Dispense in a tight, light-resistant container.
©2011, Purdue Pharmaceutical Products L.P.
Dist. by: Purdue Pharmaceutical Products L.P.
Stamford, CT 06901-3431
Revised 10/2011
300945-0B
Dericip Plus (Theophylline) Tablets
400 mg Tablets
NDC 677781-251-01
Dericip Plus (Theophylline) Tablets 400 mg Tablets NDC 677781-251-01
Dericip Plus (Theophylline) Tablets
600 mg Tablets
NDC 677781-252-01
Dericip Plus (Theophylline) Tablets 600 mg Tablets NDC 677781-252-01
Depending on the reaction of the Dericip Plus after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Dericip Plus not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Dericip Plus addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology